Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 16, 2021
Targets & Mechanisms

New targets featured at AACR signal growing opportunity in established mechanisms

Protein degraders, ion channel regulators and novel checkpoints are among new targets presented at AACR21
BioCentury | May 14, 2020
Deals

With Northern Biologics deal, Boehringer adds pair of hot topics to its immuno-oncology basket

Boehringer’s deal with Northern Biologics puts the tumor stroma in the spotlight
BioCentury | Aug 8, 2019
Distillery Therapeutics

LIF-expressing myeloid cells for DMD

BioCentury | Aug 8, 2019
Distillery Therapeutics

LIF inhibition sensitizes pancreatic cancer to chemotherapy

BioCentury | Oct 31, 2018
Distillery Therapeutics

Ophthalmic disease

BioCentury | Nov 9, 2017
Company News

Vickers to helm Northern Biologics

BioCentury | Oct 27, 2017
Preclinical News

Syros, UCSD team identifies pancreatic cancer targets

BioCentury | Oct 26, 2017
Tools & Techniques

Ripe for enhancement

How advances in enhancer profiling can aid drug development
Items per page:
1 - 10 of 44
Help Center
Username
Request a Demo
Request Training
Ask a Question